Chugai Pharmaceutical (OTCMKTS:CHGCY) Upgraded at Nomura

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by investment analysts at Nomura to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

Several other brokerages have also commented on CHGCY. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Finally, UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 0.4%

Shares of Chugai Pharmaceutical stock opened at $21.57 on Tuesday. The business has a 50 day moving average of $22.16 and a 200 day moving average of $25.24. Chugai Pharmaceutical has a 52 week low of $20.43 and a 52 week high of $34.84. The company has a market cap of $71.00 billion, a PE ratio of 23.45 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. On average, research analysts anticipate that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.